Cerevance, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cerevance, LLC - overview
Established
2016
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Established in 2016 and based in Massachusetts, US, Cerevance, LLC researches and develops therapeutics for the treatment of neurological and psychiatric disorders. In May 2026, Cerevance, LLC raised USD 20 million in series C funding from Double Point Ventures, Gates Frontier, Google Ventures, Lightstone Ventures, MQB Partners, SV Health Investors, and UPMC Enterprises. The company specializes in developing therapies for central nervous system (CNS) disorders using its proprietary NETSseq platform. This advanced technology utilizes human data and machine learning to identify targets in single cell types or those altered by disease, allowing for precision in treatment development.
Cerevance's approach provides therapeutic options with minimal off-target effects, addressing some of the CNS conditions. The company’s pipeline, including the ASCEND study for Parkinson's disease, is at the forefront of precision neuroscience and CNS disorder treatment. The company will use the May 2026 funding to support completion of its Phase 3 trial and advance its pipeline while extending its operational runway into mid-2027.
Current Investors
Lightstone Ventures, Takeda Pharmaceutical, SV Health Investors
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Mental Health Services, Pharmaceutical Research & Development
Website
www.cerevance.com/
Company Stage
Series C
Total Amount Raised
Subscriber access only
Cerevance, LLC - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.